Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$353M in Q4 2013 → $1.07B now. Hover for any quarter.
As reported for the quarter ended September 30, 2015. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| GB Global Blood Therapeutics In | 58.1% | New | 14,760,900 | $622M |
| Sage Therapeutics Inc | 25.5% | Trimmed 27% | 6,442,916 | $273M |
| Blueprint Medicines Corp | 14.7% | Unchanged | 7,393,059 | $158M |
| EB Eleven Biotherapeutics Inc | 1.1% | Unchanged | 4,841,591 | $11.7M |
| Z Zafgen Inc | 0.6% | Trimmed 93% | 210,371 | $6.72M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2015 · filed November 03, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| GB Global Blood Therapeutics In | New | +14,760,900 | +$622M | 58.1% |
| Sage Therapeutics Inc | Trimmed | −2,330,157 | −$98.6M | 25.5% |
| Z Zafgen Inc | Trimmed | −2,991,674 | −$95.6M | 0.6% |
quarter ended June 30, 2015 · filed July 30, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| FM Foundation Medicine, Inc. | Exited | −4,927,234 | −$237M | — |
| Blueprint Medicines Corp | New | +7,393,059 | +$196M | 20.4% |
| Sage Therapeutics Inc | Trimmed | −1,000,000 | −$73M | 66.7% |
| Z Zafgen Inc | Trimmed | −1,000,000 | −$34.6M | 11.5% |
quarter ended March 31, 2015 · filed April 29, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | Exited | −3,070,090 | −$344M | — |
| Bluebird Bio, Inc. | Exited | −1,215,054 | −$111M | — |
| Sage Therapeutics, Inc. | Trimmed | −1,907,935 | −$95.8M | 52.4% |
| Z Zafgen Inc. | Trimmed | −1,400,000 | −$55.5M | 17.8% |
quarter ended December 31, 2014 · filed January 26, 2015
No position changes this quarter.
quarter ended September 30, 2014 · filed October 22, 2014
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sage Therapeutics, Inc. | New | +11,681,008 | +$368M | 42.9% |
| Z Zafgen Inc. | New | +5,602,045 | +$110M | 12.8% |
| Agios Pharmaceuticals, Inc. | Trimmed | −825,000 | −$50.6M | 22.0% |
| Bluebird Bio, Inc. | Trimmed | −1,201,920 | −$43.1M | 5.1% |
quarter ended June 30, 2014 · filed July 30, 2014
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | Trimmed | −1,669,324 | −$76.5M | 38.1% |
| FM Foundation Medicine, Inc. | Trimmed | −1,642,411 | −$44.3M | 28.4% |
quarter ended March 31, 2014 · filed April 30, 2014
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| EB Eleven Biotherapeutics, Inc. | New | +4,841,591 | +$78.6M | 13.9% |
| Bluebird Bio, Inc. | Trimmed | −897,000 | −$20.4M | 9.7% |
Loading...
